Phase 4 trial in 366 adults aged 21-49 (359 analysed): high-dose recombinant quadrivalent flu vaccine gave 2.9-fold higher antibody titres against cell-grown A(H3N2) than standard-dose egg-grown or cell-grown vaccines, and responses held in frequent vaccinees.
RCTn = 366
Sullivan et al. Immunogenicity of high-dose recombinant influenza vaccine versus standard-dose egg-grown and cell-grown vaccines among frequently and infrequently vaccinated young adults in Singapore: a randomised, controlled, double-blind, single-centre, phase 4 clinical trial